|Leave a Message or Start an on-line Chat
CUSABIO developed the CLDN3 recombinant monoclonal antibody using a multi-step process. Initially, B cells were isolated from the spleen of the immunized animal, with the recombinant human CLDN3 protein employed as the immunogen during immunization. Subsequently, RNA was extracted from the B cells and converted into cDNA through reverse transcription. The gene encoding the CLDN3 antibody was extended using a degenerate primer through PCR and inserted into the vector. The recombinant vector was introduced into host cells via transfection, facilitating antibody expression. The CLDN3 recombinant monoclonal antibodies were obtained from the cell culture supernatant and purified using affinity chromatography. To confirm specificity and functionality, this antibody was validated through ELISA, demonstrating its ability to react with human CLDN3 protein.
There are currently no reviews for this product.